The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Subscribe To Our Newsletter & Stay Updated
